

Cover Story
By Paul Goldberg and Tessa Vellek
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
By Tessa Vellek
In Brief
Trending Stories
- She flew Black Hawks and battled cancer—now Col. Susan Fondy grapples with cuts to lymphedema research
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - Imaging’s ride to the bottom in clinical trials—and why it matters now
- NIH says it’s moving away from animal-based models
- The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population